Abaloparatide
FDA APPROVED
Extensively Studied
Healing
Abaloparatide
34
Amino acids
Molecular weight
Peptide
Type
Abaloparatide is an FDA-approved anabolic bone-building agent and synthetic analog of parathyroid hormone-related protein (PTHrP). It selectively activates the PTH1 receptor to stimulate new bone formation while minimizing bone resorption. In the phase III ACTIVE trial, abaloparatide showed superior BMD increases at the hip compared to teriparatide, with substantial fracture risk reduction. It was approved in the US in 2017 and EU in 2022 for postmenopausal women and men with osteoporosis at high fracture risk.
Top researched benefits
Overview of Abaloparatide
Abaloparatide works through selective activation of the parathyroid hormone 1 receptor (PTH1R), a G protein-coupled receptor expressed on osteoblasts and osteocytes. It preferentially binds to the RG (relaxed, G-protein-coupled) conformational state of PTH1R, which elicits a transient downstream cyclic AMP signaling response favoring anabolic bone formation over resorption. This selective binding pattern produces more bone-building activity with less hypercalcemic effect compared to native PTH. The result is increased cortical and trabecular bone volume, density, and improved microarchitecture.
osteoporosis fdaapproved
- FDA-approved for postmenopausal women with osteoporosis at high risk for fracture or who have failed other therapies.
- FDA-approved for men with osteoporosis at high risk for fracture or intolerant to other treatments.
bone health research
- Phase III trials demonstrated substantial reduction in vertebral and nonvertebral fractures.
- ACTIVExtend trial showed benefits of abaloparatide followed by alendronate for maintained bone protection.
Typical Dose
80 mcg
Frequency
Once daily
Cycle Duration
Up to 2 years (lifetime maximum)
Storage
Refrigerate pre-filled pen at 2-8°C, do not freeze. Discard after 30 days even if medication remains
Chemical Makeup
Key benefits
FDA-approved for osteoporosis treatment
Actively builds new bone (anabolic mechanism)
Superior hip BMD gains vs teriparatide in trials
Reduces vertebral fracture risk significantly
Reduces nonvertebral fracture risk
Lower hypercalcemia risk than teriparatide
Works through selective PTH1R activation
Benefits seen within 6 months
Community interest
This peptide is still gaining traction in the community.
PTHrP Analog | Anabolic Bone-Building Agent
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesNoAbaloparatide Molecular Information
View the scientifc details of Abaloparatide.
34
Amino Acids
Abaloparatide
Ala
Ala
Position 1
Val
Val
Position 2
Ser
Ser
Position 3
Glu
Glu
Position 4
His
His
Position 5
Gln
Gln
Position 6
Leu
Leu
Position 7
Leu
Leu
Position 8
His
His
Position 9
Asp
Asp
Position 10
Lys
Lys
Position 11
Gly
Gly
Position 12
Lys
Lys
Position 13
Ser
Ser
Position 14
Ile
Ile
Position 15
Gln
Gln
Position 16
Asp
Asp
Position 17
Leu
Leu
Position 18
Arg
Arg
Position 19
Arg
Arg
Position 20
Arg
Arg
Position 21
Glu
Glu
Position 22
Leu
Leu
Position 23
Leu
Leu
Position 24
Glu
Glu
Position 25
Lys
Lys
Position 26
Leu
Leu
Position 27
Leu
Leu
Position 28
?
?
Position 29
Lys
Lys
Position 30
Leu
Leu
Position 31
His
His
Position 32
Thr
Thr
Position 33
Ala
Ala
Position 34
Molecular Weight
3961DaChain Length
34Amino AcidsType
PeptideAbaloparatide Protocols
Abaloparatide is administered as a once-daily subcutaneous injection in the periumbilical (around the navel) region of the abdomen. It comes in pre-filled pen devices (Tymlos). Cumulative lifetime use is limited to 2 years due to theoretical osteosarcoma risk observed in rodent studies. A transdermal patch formulation is also in development.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Osteoporosis treatment | 80 | 1 week range | SubQ (periumbilical abdomen) |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Store pen refrigerated at 2-8°C (do not freeze)
- Allow to reach room temperature before injection
- Attach new needle for each injection
- Inject subcutaneously in periumbilical region
- Rotate injection sites
- Discard pen after 30 days even if medication remains
Abaloparatide Cycle
The Abaloparatide Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Month 1-3
- Bone formation markers increase; initial BMD changes begin
- Month 3-6
- Significant BMD increases at spine, hip, and femur
- Month 6-12
- Continued bone density improvements; fracture risk reduction
- Month 12-18
- Maximum benefits in ACTIVE trial; substantial fracture reduction
- Month 18-24
- Transition to maintenance therapy (e.g., bisphosphonates) recommended
Dosing tools
Abaloparatide Peptide Dosage Calculator
Calculate peptide doses with our visual syringe guide.
mg
Enter the total amount of peptide in the vial in milligrams (as stated on the label).
The dose you want to inject per administration, in mcg or mg.
1,000 mcg = 1 mg
1 mL
2 mL
3 mL
5 mL
Custom
Volume of bacteriostatic water you add to reconstitute the powder. Use BAC water for preservation.
Injection Results
Based on your vial and dilution inputs.
Abaloparatide
SINGLE COMPOUNDVolume per injection
0.05
mL
Concentration
10.00
mg/mL
Doses per vial
20
doses
Total injections per vial
20 injections
How it works
Based on a 10 mg Abaloparatide vial diluted with 1 mL of bacteriostatic water, each 500 mcg injection equals 0.05 mL.
1mL / 100 units
5 units
0.050 mL
Reference Guide
Dosing Cycle
- Peptide
- Abaloparatide
- Dosing
- 80 mcg
- Dosing Frequency
- Once daily
- Cycle Duration
- Up to 2 years (lifetime maximum)
- Storage
- Refrigerate pre-filled pen at 2-8°C, do not freeze. Discard after 30 days even if medication remains
Note: Triple agonist; microdose for fewer side effects
Reconstitution Tips
- Use bacteriostatic water (BAC) — contains 0.9% benzyl alcohol for preservation
- Inject water slowly — aim down the vial wall, not directly onto powder
- Never shake — gently swirl or roll the vial until dissolved
- Store properly — refrigerate at 2-8°C after reconstitution
- Use within 28 days — most reconstituted peptides remain stable for about 4 weeks
- Keep sterile — always clean vial tops with alcohol before drawing
Peptide Interactions
Research suggestions of Abaloparatide interactions with other common peptides and substances.
Healing
ter
Teriparatide
AVOID
Do not use concurrently; both are PTH receptor agonists. Choose one or use sequentially.
Side effects
Avoid: Do not take Abaloparatide with Teriparatide.
Contraindications
Paget's disease of bone
Prior external beam or implant radiation therapy to skeleton
Bone metastases or history of skeletal malignancies
Metabolic bone diseases other than osteoporosis
Pre-existing hypercalcemia
Pregnancy or nursing
Cumulative use exceeding 2 years lifetime
Stop signs
Signs of hypercalcemia (confusion, fatigue, excessive thirst)
Persistent bone pain
Severe dizziness or fainting
Allergic reactions
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What is a peptide dosage calculator?
A peptide dosage calculator is a free tool that converts your vial size, bacteriostatic water volume, and target dose into an exact syringe draw volume. Instead of doing the reconstitution math by hand, you enter three inputs and instantly get the concentration of your solution and how many milliliters or syringeunits to draw. This calculator works for single peptide compounds and multi-peptide blends.
How do I calculate peptide dosage from a vial?
To calculate your peptide dose, divide the total peptide content of your vial in micrograms by the volume of bacteriostatic water you added in milliliters. This gives you your solution concentration in mcg/mL. Then divide your target dose by that concentration to get your draw volume. For example, a 5mg (5,000 mcg) vial reconstituted with 2mL of BAC water gives a concentration of 2,500 mcg/mL. A 250 mcg dose would require drawing 0.1mL. This calculator automates all of those steps instantly.
How much Bacteriostatic water should I add to a peptide vial?
Most people add 2mL to 3mL of bacteriostatic water per vial, but the right amount depends on the dose you want to draw and the syringe size you are using. Adding 1mL to a 5mg vial gives you a concentration of 5,000 mcg/mL, making each dose very small in volume. Adding 2mL gives you 2,500 mcg/mL, which is easier to measure on a standard insulin syringe. A general guideline is to choose a volume that puts your typical dose somewhere between 10 and 30 units on a U-100 syringe. Use the calculator above to test different water volumes and find what works for your dose.
How are peptides different from proteins?
Both are made of amino acids, but peptides are much smaller than proteins. Because of their tiny size, peptides can act like tiny messengers in the body, sending specific signals to your cells to tell them exactly what to do.
AbaloparatideResearch References
Abaloparatide is an extensively studied compound
Abaloparatide
Abaloparatide is an extensively studied compound
Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis (ACTIVE Trial)
Abaloparatide showed substantial reduction in vertebral fractures and greater BMD increases at spine, hip, and femur compared to placebo and teriparatide.
n.d.
ACTIVExtend Trial: Abaloparatide Followed by Alendronate
18 months abaloparatide followed by alendronate significantly reduced vertebral and nonvertebral fractures.
n.d.
Phase 2 Dose-finding Study of BA058 in Postmenopausal Women
Significant BMD increases at 40 and 80 mcg doses; abaloparatide showed superior anabolic effects on hips vs teriparatide.
n.d.
Profile of Abaloparatide and Its Potential in Postmenopausal Osteoporosis
Abaloparatide preferentially binds RG conformational state of PTH1R, producing more anabolic bone effects.
n.d.